Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.
| Data(s) |
15/10/2015
|
|---|---|
| Formato |
4505 - 4507 |
| Identificador |
http://www.ncbi.nlm.nih.gov/pubmed/26307134 1078-0432.CCR-15-1613 Clin Cancer Res, 2015, 21 (20), pp. 4505 - 4507 1078-0432 |
| Relação |
Clin Cancer Res 10.1158/1078-0432.CCR-15-1613 |
| Tipo |
Journal Article |
| Cobertura |
United States |
| Resumo |
Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer. |
| Idioma(s) |
ENG |
| Palavras-Chave | #Amyloid Precursor Protein Secretases #Animals #Antineoplastic Combined Chemotherapy Protocols #Humans #Male #Prostatic Neoplasms |
